Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300963 · ClinicalTrials.gov registry record · Phase 2
Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 275
- Enrollment target
NCT00300963 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 275 participants.
The verdict
NCT00300963, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Interventions
- DRUG Talnetant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300963
The ClinicalTrials.gov registry entry for NCT00300963 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talnetant is the first listed.
NCT00300963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300963 about?
NCT00300963 is a clinical study titled "Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients". The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
What is the current status of trial NCT00300963?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 275 participants. The study started on 2004-12. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00300963?
The interventions under investigation include: Talnetant (DRUG).
Who is sponsoring clinical trial NCT00300963?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.